Artis BioSolutions

Executive Summary

Artis BioSolutions is a San Diego-based private biotech founded in 2020 that accelerates the development and commercialization of genetic medicines and biologics. The company offers a comprehensive suite of technology, expertise, and operational support to streamline the path from discovery to commercial production, focusing on advanced modalities such as nucleic acids, lipid nanoparticles (LNPs), peptides, and enzymes. As a Phase 1 company, Artis aims to address bottlenecks in the development of complex therapies, leveraging its platform to reduce timelines and costs for partners. While the company has not disclosed total funding or valuation, its early-stage status suggests a focus on building capabilities and securing initial partnerships. The biotech ecosystem's increasing demand for outsourced development services, particularly for RNA and LNP-based therapeutics, positions Artis favorably for growth. However, with no publicly available pipeline or revenue data, the company remains in an early validation phase, and its success hinges on attracting clients and completing development milestones.

Upcoming Catalysts (preview)

• Q2 2026Series A Funding Round70% success
• Q4 2026Major Partnership with a Top Biopharma Company50% success
• Q3 2026Expansion of Manufacturing Capacity or Facility60% success